CRNX - NASDAQ

Crinetics Pharmaceuticals, Inc.

CRNX·NASDAQ

$33.09

+0.98%

HealthcareBiotechnology

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$3.49B

EPS-4.9500

P/E Ratio-6.68

Earnings Date08/06/2026

1.14B

Assets

-21%

3Y+222.0%

5Y+519.0%

10Y+8913.0%

143.41M

Total Liabilities

31%

3Y+300.0%

5Y+887.0%

10Y+663.0%

992.08M

Total Equity

-25%

3Y+214.0%

5Y+487.0%

10Y-16091.0%

Crinetics Pharmaceuticals, Inc. Funding & Solvency Profile

CRNX · NASDAQ

Current Assets

Cash & Cash Equivalents101.54M

Net Receivables592.00K

Inventory2.02M

Other Current Assets17.84M

Total Current Assets1 B

Non-Current Assets

Property, Plant & Equipment54.79M

Goodwill & Intangible Assets0.00

Long-Term Investments800.00K

Other Non-Current Assets22.33M

Total Non-Current Assets78 M

Total Assets

1.14B

Financial Health Analysis

Current Ratio

12.32x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.14x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

963 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

92% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Crinetics Pharmaceuticals, Inc. Balance Sheet

CRNX • NASDAQ

Crinetics Pharmaceuticals, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	101.5M	264.5M	54.9M	32.7M	200.7M	93.1M	40.3M	45M	14.2M	12.2M
Short-Term Investments	926.4M	1.1B	503.7M	301.8M	133M	77.8M	78.1M	118.9M	0.0	0.0
Cash & Short-Term Investments	1B	1.4B	558.6M	334.4M	333.7M	170.9M	118.4M	163.9M	14.2M	12.2M
Net Receivables	592K	8.5M	9.4M	2.4M	2M	1.8M	1.4M	0.0	734K	72K
Accounts Receivables	592K	0.0	0.0	0.0	2M	0.0	225K	568K	231K	0.0
Other Receivables	0.0	8.5M	9.4M	2.4M	0.0	1.8M	1.2M	1M	503K	72K
Inventory	2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	141K	98K
Prepaids	0.0	11.1M	4.7M	5.8M	9M	3.8M	2.5M	876K	239K	0.0
Other Current Assets	17.8M	1.7M	1.6M	2.5M	0.0	1M	1.1M	0.0	0.0	43K
Total Current Assets	1B	1.4B	574.2M	345.2M	344.7M	177.5M	123.3M	166.7M	15.2M	12.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	54.8M	55.6M	57.4M	5M	4.7M	5.4M	6.5M	4.2M	400K	224K
Long-Term Investments	800K	800K	1.8M	2M	1M	0.0	500K	500K	0.0	0.0
Tax Assets	9.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	22.3M	2.8M	2M	37K	568K	540K	82K	0.0	33K	10K
Total Non-Current Assets	87.2M	59.2M	61.2M	7M	6.3M	6M	7M	4.7M	433K	234K
Total Assets	1.1B	1.4B	635.4M	352.2M	351M	183.4M	130.4M	171.4M	15.6M	12.6M
LIABILITIES
CURRENT LIABILITIES
Total Payables	22.6M	5.9M	6.5M	6.9M	3.4M	3.5M	2.7M	1.5M	403K	340K
Accounts Payable	22.6M	5.9M	6.5M	6.9M	3.4M	3.5M	2.7M	1.5M	403K	340K
Accrued Expenses	35.6M	44.5M	14.5M	9.1M	5M	2.1M	2.1M	5.9M	494K	501K
Short Term Debt	6.5M	0.0	4.2M	1.1M	0.0	0.0	724K	0.0	0.0	49K
Capital Lease Obligations (Current)	0.0	7.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	1.2M	2.2M	2.1M	2.2M	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	19.2M	10K	16.6M	8.5M	7.5M	4.9M	2.8M	590K	0.0	0.0
Total Current Liabilities	85.1M	59.7M	43.9M	27.7M	16M	10.5M	8.3M	7.9M	897K	890K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	163K
Deferred Revenue (Non-Current)	3.8M	4.7M	4.8M	6.1M	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	9.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	3.2M	829K	0.0	0.0	2K	23K	49K	3.3M	29.7M	17.8M
Total Non-Current Liabilities	58.3M	50.1M	52.3M	8.1M	3.1M	4M	4.9M	3.3M	29.7M	17.9M
Capital Lease Obligations	42.1M	51.7M	47.6M	2M	3.1M	4M	4.8M	0.0	0.0	0.0
Total Liabilities	143.4M	109.8M	96.2M	35.8M	19.1M	14.5M	13.2M	11.2M	30.6M	18.8M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-374.9M	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	171.4M	29.7M	17.7M
Common Stock	2.4B	2.3B	1.2B	759.4M	607.6M	336.5M	210.8M	24K	1K	1K
Additional Paid-In Capital	0.0	0.0	0.0	0.0	0.0	0.0	0.0	203.5M	1.2M	900K
Retained Earnings	-1.4B	-952.1M	-653.7M	-439.2M	-275.3M	-167.6M	-93.8M	-43.4M	-16.3M	-7.1M
Accumulated Other Comprehensive Income/Loss	1.8M	963K	977K	-3.9M	-382K	25K	148K	61K	-304K	-182K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	304K	185K
Total Stockholders' Equity	992.1M	1.3B	539.1M	316.3M	331.9M	168.9M	117.1M	-43.4M	-15M	-6.2M
Total Equity	992.1M	1.3B	539.1M	316.3M	331.9M	168.9M	117.1M	-43.4M	-15M	-6.2M
SUMMARY
Total Liabilities & Equity	1.1B	1.4B	635.4M	352.2M	351M	183.4M	130.4M	-32.2M	15.6M	12.6M
Total Investments	926.4M	1.1B	505.4M	303.7M	134M	77.8M	78.6M	118.9M	0.0	0.0
Total Debt	48.5M	51.7M	51.7M	3.1M	3.1M	4M	5.6M	0.0	0.0	212K
Net Debt	-53M	-212.8M	-3.2M	-29.6M	-197.6M	-89.1M	-34.8M	-45M	-14.2M	-11.9M
Shares Outstanding	94,891,055	94,891,055	94,891,055	94,891,055	94,891,055	94,891,055	94,891,055	94,891,055	94,891,055	94,891,055

SEC Filings

CRNX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 29, 2026	June 18, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 10, 2026	April 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 23, 2026	March 17, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 03, 2026	February 27, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 26, 2026	January 20, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 13, 2026	January 13, 2026	2026	View Filing

Showing 1 to 10 of 156 filings

Related Guides

Blog Categories

Continue your CRNX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.